Scientists are increasingly investigating retatrutide, a promising treatment developed by Eli Lilly, as a significant step in body loss . Distinct from many previous approaches, retatrutide is a twin-action compound targeting simultaneously GLP-1 and GIP, substances that impact satiety and blood